Differential Immune Signatures in the Tumor Microenvironment are Associated with Colorectal Cancer Racial Disparities: A Cohort Study of Biorepository Data

Thomas Curran, Zequn Sun, Brielle Gerry, Victoria J. Findlay, Kristin Wallace, Zihai Li, Chrystal M. Paulos, Marvella E. Ford, Mark P. Rubinstein, Dongjun Chung, E. Ramsay CampResearch Square 2020 · DOI

Abstract

Background: Disparities in colorectal cancer (CRC) outcomes may be due to a more aggressive phenotype in African American patients in the setting of decreased tumor immunity. This study compares the immunogenomic signatures of CRC from African American (AA) and European American (EA) patients to explore underlying molecular factors.

Methods: Data from 254 CRC patients (58 AA, 196 EA) were identified from The Cancer Genome Atlas (TCGA). Immunophenotype signatures were established using cellular deconvolution, and comparisons were made regarding survival and immune cellular components, controlling for sex, age, and disease stage.

Results: AA patients exhibited decreased progression-free survival (p=0.04). Tumors from AA patients showed a reduced fraction of macrophages and CD8+ T cells and an increased fraction of B cells compared to EA patients. Immunostimulatory and immunoinhibitory gene profiles also differed significantly by race.

Conclusions: Differences in the tumor immune microenvironment (TME) may contribute to survival disparities and provide targeted therapeutic opportunities.

Introduction

In the United States, African Americans face a 30–50% higher mortality rate from colorectal cancer compared to European Americans. While socioeconomic factors are critical, approximately 25% of this survival disparity remains unexplained. This research investigates whether the "missing link" lies in the biological composition of the tumor microenvironment (TME), specifically how the immune system recognizes and attacks cancer cells across different racial groups.

Methods and Data Sources

The study utilized publicly available data from The Cancer Genome Atlas (TCGA), specifically the colorectal adenocarcinoma (COAD/READ) datasets. The researchers employed CIBERSORT, a cellular deconvolution tool, to estimate the proportions of 22 immune cell types from bulk gene expression profiles. Statistical significance was determined using multivariable linear regression to account for potential confounders like age, sex, and cancer stage.

Key Results

Survival and Cellular Disparities

African American patients demonstrated significantly lower progression-free survival (p=0.04), with a median of 1,678 days compared to EA patients, whose median was not reached during the study period. Analysis of the TME revealed that AA tumors are often "immunologically cold."

Summary of immune cell fractions showing significant differences in CD8+ T cells, B cells, and Macrophages between AA and EA cohorts.

As shown in the data, AA tumors had a significantly reduced fraction of CD8+ T cells (0.10 vs 0.12, p=0.03) and macrophages (0.34 vs 0.40, p=0.003). Conversely, they exhibited a higher fraction of B cells (0.08 vs 0.05, p=0.002).

Molecular Signatures and Gene Expression

The study identified a critical downregulation of antigen-presentation machinery in AA tumors. Specifically, molecules like MHC Class I and II, which are essential for T cell recognition, were expressed at lower levels. Furthermore, several key "checkpoint" and immunostimulatory genes were found to be downregulated in the AA cohort.

Functional significance and clinical evidence for genes found to be downregulated in African American vs. European American CRC.

Notable downregulated genes include PDCD1 (PD-1), CD274 (PD-L1), and LAG3. While these are common targets for immunotherapy, their low baseline expression in AA patients suggests a fundamentally different immune exhaustion profile and potentially different responses to standard checkpoint inhibitors.

Discussion and Future Directions

The findings suggest that the "colder" immune microenvironment in African American CRC patients—characterized by fewer killer T cells and impaired antigen presentation—may drive more aggressive disease progression.

However, the study is limited by the relatively small sample size of AA patients in the TCGA (n=58) and a lack of granular socioeconomic data. Future research using spatial transcriptomics is necessary to determine if immune cells are successfully penetrating the tumor core or remaining sequestered in the stroma. These biological insights underscore the need for clinical trials that incorporate race-specific biomarkers to optimize therapeutic outcomes for all patient populations.

Summary updated

Abstract

<title>Abstract</title> <bold>Background: </bold>Disparities in colorectal cancer outcomes may be due to a more aggressive phenotype in African American patients in the setting of a decreased tumor immunity, though the precise mechanism for this result has not been well elucidated. To explore the molecular factors underlying colorectal cancer disparities, we compared the immunogenomic signatures of colorectal cancer from African American and European American patients.<bold>Methods: </bold>We identified all colorectal cancer patients from the publicly available Cancer Genome Atlas for whom race and survival data are available. Immunophenotype signatures were established for African American and European American patients. Comparisons were made regarding survival and a multivariable linear regression model was created to determine the association of immune cellular components with race. Differential gene expression was also assessed. <bold>Results: </bold>Of the 254 patients identified, 58 (23%) were African American and 196 (77%) were European American. African American patients had a decreased progression free survival (p=0.04). Tumors from African American patients displayed a reduced fraction of macrophages and CD8<sup>+</sup> T cells and an increased fraction of B cells compared with tumors from European Americans. Differences persisted when controlling for sex, age and disease stage. Immunostimulatory and immunoinhibitory gene profiles including MHC expression differed by race. <bold>Conclusions: </bold>Differences in the tumor immune microenvironment of African American as compared to European American colorectal cancer specimens may play a role in the survival differences between the groups. These differences may provide targeted therapeutic opportunities.
BibTeX
@inproceedings{curran2020differential,
  author = {Thomas Curran and Zequn Sun and Brielle Gerry and Victoria J. Findlay and Kristin Wallace and Zihai Li and Chrystal M. Paulos and Marvella E. Ford and Mark P. Rubinstein and Dongjun Chung and E. Ramsay Camp},
  title = {{Differential Immune Signatures in the Tumor Microenvironment are Associated with Colorectal Cancer Racial Disparities: A Cohort Study of Biorepository Data}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.3.rs-41544/v1},
}
Figure